The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

L R Yates, J Seoane, C Le Tourneau, L L Siu, R Marais, S Michiels, J C Soria, P Campbell, N Normanno, A Scarpa, J S Reis-Filho, J Rodon, C Swanton, F Andre

Research output: Contribution to journalArticle

Abstract

Background: Precision medicine is rapidly evolving within the field of oncology and has brought many new concepts and terminologies that are often poorly defined when first introduced, which may subsequently lead to miscommunication within the oncology community. The European Society for Medical Oncology (ESMO) recognises these challenges and is committed to support the adoption of precision medicine in oncology. To add clarity to the language used by oncologists and basic scientists within the context of precision medicine, the ESMO Translational Research and Personalised Medicine Working Group has developed a standardised glossary of relevant terms.

Materials and methods: Relevant terms for inclusion in the glossary were identified via an ESMO member survey conducted in Autumn 2016, and by the ESMO Translational Research and Personalised Medicine Working Group members. Each term was defined by experts in the field, discussed and, if necessary, modified by the Working Group before reaching consensus approval. A literature search was carried out to determine which of the terms, 'precision medicine' and 'personalised medicine', is most appropriate to describe this field.

Results: A total of 43 terms are included in the glossary, grouped into five main themes-(i) mechanisms of decision, (ii) characteristics of molecular alterations, (iii) tumour characteristics, (iv) clinical trials and statistics and (v) new research tools. The glossary classes 'precision medicine' or 'personalised medicine' as technically interchangeable but the term 'precision medicine' is favoured as it more accurately reflects the highly precise nature of new technologies that permit base pair resolution dissection of cancer genomes and is less likely to be misinterpreted.

Conclusions: The ESMO Precision Medicine Glossary provides a resource to facilitate consistent communication in this field by clarifying and raising awareness of the language employed in cancer research and oncology practice. The glossary will be a dynamic entity, undergoing expansion and refinement over the coming years.

Original languageEnglish
JournalAnnals of Oncology
DOIs
Publication statusPublished - 2018

Fingerprint

Precision Medicine
Translational Medical Research
Medical Oncology
Language
Neoplasms
Research
Terminology
Base Pairing
Dissection
Consensus
Communication
Clinical Trials
Genome

Keywords

  • Journal Article

Cite this

Yates, L. R., Seoane, J., Le Tourneau, C., Siu, L. L., Marais, R., Michiels, S., ... Andre, F. (2018). The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology. https://doi.org/10.1093/annonc/mdx707

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. / Yates, L R; Seoane, J; Le Tourneau, C; Siu, L L; Marais, R; Michiels, S; Soria, J C; Campbell, P; Normanno, N; Scarpa, A; Reis-Filho, J S; Rodon, J; Swanton, C; Andre, F.

In: Annals of Oncology, 2018.

Research output: Contribution to journalArticle

Yates, LR, Seoane, J, Le Tourneau, C, Siu, LL, Marais, R, Michiels, S, Soria, JC, Campbell, P, Normanno, N, Scarpa, A, Reis-Filho, JS, Rodon, J, Swanton, C & Andre, F 2018, 'The European Society for Medical Oncology (ESMO) Precision Medicine Glossary', Annals of Oncology. https://doi.org/10.1093/annonc/mdx707
Yates, L R ; Seoane, J ; Le Tourneau, C ; Siu, L L ; Marais, R ; Michiels, S ; Soria, J C ; Campbell, P ; Normanno, N ; Scarpa, A ; Reis-Filho, J S ; Rodon, J ; Swanton, C ; Andre, F. / The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. In: Annals of Oncology. 2018.
@article{966c9eb4769b4f6ab24082ad015958bb,
title = "The European Society for Medical Oncology (ESMO) Precision Medicine Glossary",
abstract = "Background: Precision medicine is rapidly evolving within the field of oncology and has brought many new concepts and terminologies that are often poorly defined when first introduced, which may subsequently lead to miscommunication within the oncology community. The European Society for Medical Oncology (ESMO) recognises these challenges and is committed to support the adoption of precision medicine in oncology. To add clarity to the language used by oncologists and basic scientists within the context of precision medicine, the ESMO Translational Research and Personalised Medicine Working Group has developed a standardised glossary of relevant terms.Materials and methods: Relevant terms for inclusion in the glossary were identified via an ESMO member survey conducted in Autumn 2016, and by the ESMO Translational Research and Personalised Medicine Working Group members. Each term was defined by experts in the field, discussed and, if necessary, modified by the Working Group before reaching consensus approval. A literature search was carried out to determine which of the terms, 'precision medicine' and 'personalised medicine', is most appropriate to describe this field.Results: A total of 43 terms are included in the glossary, grouped into five main themes-(i) mechanisms of decision, (ii) characteristics of molecular alterations, (iii) tumour characteristics, (iv) clinical trials and statistics and (v) new research tools. The glossary classes 'precision medicine' or 'personalised medicine' as technically interchangeable but the term 'precision medicine' is favoured as it more accurately reflects the highly precise nature of new technologies that permit base pair resolution dissection of cancer genomes and is less likely to be misinterpreted.Conclusions: The ESMO Precision Medicine Glossary provides a resource to facilitate consistent communication in this field by clarifying and raising awareness of the language employed in cancer research and oncology practice. The glossary will be a dynamic entity, undergoing expansion and refinement over the coming years.",
keywords = "Journal Article",
author = "Yates, {L R} and J Seoane and {Le Tourneau}, C and Siu, {L L} and R Marais and S Michiels and Soria, {J C} and P Campbell and N Normanno and A Scarpa and Reis-Filho, {J S} and J Rodon and C Swanton and F Andre",
year = "2018",
doi = "10.1093/annonc/mdx707",
language = "English",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",

}

TY - JOUR

T1 - The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

AU - Yates, L R

AU - Seoane, J

AU - Le Tourneau, C

AU - Siu, L L

AU - Marais, R

AU - Michiels, S

AU - Soria, J C

AU - Campbell, P

AU - Normanno, N

AU - Scarpa, A

AU - Reis-Filho, J S

AU - Rodon, J

AU - Swanton, C

AU - Andre, F

PY - 2018

Y1 - 2018

N2 - Background: Precision medicine is rapidly evolving within the field of oncology and has brought many new concepts and terminologies that are often poorly defined when first introduced, which may subsequently lead to miscommunication within the oncology community. The European Society for Medical Oncology (ESMO) recognises these challenges and is committed to support the adoption of precision medicine in oncology. To add clarity to the language used by oncologists and basic scientists within the context of precision medicine, the ESMO Translational Research and Personalised Medicine Working Group has developed a standardised glossary of relevant terms.Materials and methods: Relevant terms for inclusion in the glossary were identified via an ESMO member survey conducted in Autumn 2016, and by the ESMO Translational Research and Personalised Medicine Working Group members. Each term was defined by experts in the field, discussed and, if necessary, modified by the Working Group before reaching consensus approval. A literature search was carried out to determine which of the terms, 'precision medicine' and 'personalised medicine', is most appropriate to describe this field.Results: A total of 43 terms are included in the glossary, grouped into five main themes-(i) mechanisms of decision, (ii) characteristics of molecular alterations, (iii) tumour characteristics, (iv) clinical trials and statistics and (v) new research tools. The glossary classes 'precision medicine' or 'personalised medicine' as technically interchangeable but the term 'precision medicine' is favoured as it more accurately reflects the highly precise nature of new technologies that permit base pair resolution dissection of cancer genomes and is less likely to be misinterpreted.Conclusions: The ESMO Precision Medicine Glossary provides a resource to facilitate consistent communication in this field by clarifying and raising awareness of the language employed in cancer research and oncology practice. The glossary will be a dynamic entity, undergoing expansion and refinement over the coming years.

AB - Background: Precision medicine is rapidly evolving within the field of oncology and has brought many new concepts and terminologies that are often poorly defined when first introduced, which may subsequently lead to miscommunication within the oncology community. The European Society for Medical Oncology (ESMO) recognises these challenges and is committed to support the adoption of precision medicine in oncology. To add clarity to the language used by oncologists and basic scientists within the context of precision medicine, the ESMO Translational Research and Personalised Medicine Working Group has developed a standardised glossary of relevant terms.Materials and methods: Relevant terms for inclusion in the glossary were identified via an ESMO member survey conducted in Autumn 2016, and by the ESMO Translational Research and Personalised Medicine Working Group members. Each term was defined by experts in the field, discussed and, if necessary, modified by the Working Group before reaching consensus approval. A literature search was carried out to determine which of the terms, 'precision medicine' and 'personalised medicine', is most appropriate to describe this field.Results: A total of 43 terms are included in the glossary, grouped into five main themes-(i) mechanisms of decision, (ii) characteristics of molecular alterations, (iii) tumour characteristics, (iv) clinical trials and statistics and (v) new research tools. The glossary classes 'precision medicine' or 'personalised medicine' as technically interchangeable but the term 'precision medicine' is favoured as it more accurately reflects the highly precise nature of new technologies that permit base pair resolution dissection of cancer genomes and is less likely to be misinterpreted.Conclusions: The ESMO Precision Medicine Glossary provides a resource to facilitate consistent communication in this field by clarifying and raising awareness of the language employed in cancer research and oncology practice. The glossary will be a dynamic entity, undergoing expansion and refinement over the coming years.

KW - Journal Article

U2 - 10.1093/annonc/mdx707

DO - 10.1093/annonc/mdx707

M3 - Article

C2 - 29140430

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -